← Back to Clinical Trials
Recruiting Phase 2 NCT07294131

NCT07294131 Targeting Muscle Strength Loss Due to Hospitalization in Older Adults by Blood-flow Restriction Combined With an Electromyography-driven Serious Game.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07294131
Status Recruiting
Phase Phase 2
Sponsor Vrije Universiteit Brussel
Condition Hospital Associated Disability
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2026-06-05
Primary Completion 2029-01-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Gamified isometric strength training with blood flow restrictionStandard Physiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 120 participants in total. It began in 2026-06-05 with a primary completion date of 2029-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study investigates a new training method designed to help older adults preserve their muscle strength during hospitalization. When older adults are admitted to the hospital and spend long periods in bed, their muscles can weaken very quickly. This condition is known as hospital-associated disability (HAD), and it can lead to longer hospital stays, reduced independence, and an increased risk of complications or even death. Conventional strength training with heavy weights is often too demanding or unsafe for frail patients, especially just after surgery or illness. As a safer alternative, this study combines light muscle exercises with a medically validated technique called blood flow restriction (BFR), which gently reduces blood flow to the leg to boost the effects of light exercises. To make training more engaging and personalized, the GHOSTLY+ system was developed. This system consists of a game played on a tablet that responds to muscle activity through sensors placed on the skin. While playing, patients perform isometric muscle contractions (exercises where the muscles tighten without moving the joint) that help to maintain and rebuild strength. The system was carefully designed in collaboration with patients and therapists, and it has already been tested in a smaller pilot study at UZ Brussel. The current study is a multicenter randomized controlled trial, taking place at UZ Brussel, UZ Antwerpen, and UZ Leuven. A total of 120 patients aged 65 or older will be recruited, all of whom are hospitalized and are unable to bear weight or transfer (e.g., from lying to seated position). Participants will be randomly assigned to one of two groups. One group receives standard physiotherapy. The other group receives standard therapy plus the GHOSTLY+ training program. Those in the GHOSTLY+ group will train at least five times per week for two weeks, or until discharge from the hospital. Each training session lasts approximately 30 minutes and involves three sets of 12 muscle contractions, guided by the game. The difficulty is adapted to the individual's muscle strength, which is measured at the beginning of the training using a built-in calibration protocol. During the session, a smart cuff is applied to the upper leg to partially restrict blood flow - a technique shown to safely enhance muscle adaptation. The cuff is inflated to 50% of the individual's arterial occlusion pressure and deflated after the session ends. Before beginning, participants receive a short training session with a physiotherapist. Our pilot study (Debeuf et al., 2025) shows that most patients can use the system independently after about one hour of instruction. Measurements and evaluations take place at three timepoints: before starting the training, after one week, and again at discharge. The main goal is to assess leg muscle strength, which will be measured using a handheld device called a dynamometer. In addition, researchers will collect information on: * Muscle mass, via ultrasound of the thigh muscle * Functional capacity, using a 30-second sit-to-stand test and a walking scale (Functional Ambulation Category) * An index of independence in activities of daily living (Katz scale) * Cognitive functioning, using the Mini-Mental State Examination (MMSE) * Time spent bedridden and total length of hospital stay * Therapy adherence and user experience, via usage data and questionnaires * Muscle activity signals, such as fatigue, recorded during gameplay * Implementation outcomes (collected via surveys, interview, site logbooks) The study will also assess how easily the GHOSTLY+ system can be implemented in real hospital environments. This includes evaluations of user satisfaction, therapist feedback, and how consistently the system is used across hospital settings. Information will be gathered through structured interviews, surveys, and data logs from the app. These insights are crucial to understanding whether GHOSTLY+ can be broadly adopted in other hospitals in the future. Blood flow restriction training is considered very safe when applied correctly and is already used in rehabilitation clinics and sports medicine worldwide. Over 300,000 sessions have been conducted internationally, with a very low rate of complications. Minor discomfort, such as temporary tightness or muscle fatigue, may occur, but the risk of serious side effects is extremely small. By participating in this study, patients may benefit from improved muscle strength, reduced time spent in bed, and greater physical independence at discharge. The study also contributes to the development of more effective and enjoyable rehabilitation methods for older adults in hospitals.

Eligibility Criteria

PATIENTS Inclusion Criteria: * Hospitalized, and expected to remain hospitalized for approximately 14 days * 65+ yrs * Unable to bear weight or transfer independently and at high risk of muscle strength loss due to prolonged immobility Exclusion Criteria: * Contraindications for physical exercise as assessed by the treating physician using the risk assessment tool proposed by Kacin et al. (2015) (can be overruled by the physician) * Contraindications for blood flow restriction as assessed by the treating physician (can be overruled by the physician) * Cognitive impairment (MMSE score \< 19) * Any condition that renders the patient unable to understand instructions or safely interact with the GHOSTLY+ system THERAPISTS Inclusion Criteria: Therapists will be included if * They are licensed physiotherapists employed at one of the three participating clinical sites * They are involved in the daily rehabilitation of hospitalized older adults. Exclusion Criteria: Therapists will be excluded from participation if * They are unable or unwilling to complete the GHOSTLY+ training * They are not directly involved in the care of eligible patients during the study period * They express any conflict of interest or ethical concern that may compromise the integrity of the study

Contact & Investigator

Central Contact

Eva Swinnen, prof. dr.

✉ eva.swinnen@vub.be

📞 +32 (0)2 477 45 27

Principal Investigator

Eva Swinnen, prof. dr.

PRINCIPAL INVESTIGATOR

Vrije Universiteit Brussel

Frequently Asked Questions

Who can join the NCT07294131 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Hospital Associated Disability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07294131 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07294131 currently recruiting?

Yes, NCT07294131 is actively recruiting participants. Contact the research team at eva.swinnen@vub.be for enrollment information.

Where is the NCT07294131 trial being conducted?

This trial is being conducted at Antwerp, Belgium, Brussels, Belgium, Leuven, Belgium.

Who is sponsoring the NCT07294131 clinical trial?

NCT07294131 is sponsored by Vrije Universiteit Brussel. The principal investigator is Eva Swinnen, prof. dr. at Vrije Universiteit Brussel. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology